Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Harb, Wael A
  • Sessa, Cristiana
  • Hirte, Holger
  • Kaye, Stanley B
  • Banerjee, Susana N
  • Christinat, Alexandra
  • Simantov, Ronit
  • Singh, Margaret
  • Sternberg, David W
  • Light, Rebecca
  • Poondru, Srinivasu
  • Naumann, R Wendel

publication date

  • May 20, 2013